Adverse event reporting of mirtazapine: A disproportionality analysis of FDA adverse event reporting system (FAERS) database from 2004-2024

Comprehensive Summary

The study being conducted by Guo et al. aims to evaluate the safety profile of mirtazapine, which is an antidepressant commonly used to treat major depressive disorder (MDD), as welll as other psychiatric conditions. Researchers analyzed over 14,000 adverse event reports and focused on incidents where mirtazapine was the primary suspected drug. Researchers used statistical signal-detection methods to identify safety signals at the System Organ Class (SOC) level and the Preferred Term (PT) level. Most patients were aged 18-64 and were female, and 10.7% of reported causes resulted in death and 26.4% resulted in hospitalization. At the systemic level, nervous system disorders contained the highest signal, including anxiety and irritability. At the specific event level, researchers found strong signals in suicide attempts, sedation, inefficiency of the drug, and product usage for unapproved indications. Additionally, there were several novel adverse effects that were not previously reported on drug labels, including ECG changes, coma, insomnia, and drug interactions. Most adverse effects were found to occur within the first month of treatment, but a second wave of adverse symptoms were observed one year after beginning treatment. Researchers have emphasized that close monitoring is paramount in mirtazapine prescription, especially during the first month and during long-term use. Overall, the study is important in recognizing the need for vigilance in pharmacology and in ensuring clinical safety through monitoring.

Outcomes and Implications

Mirtazapine works by increasing norepinephrine and serotonin activity and blocking certain serotonin and histamine receptors. The drug treats depression and insomnia, causes fewer sexual side effects than other antidepressants such as SSRIs, and has a relatively fast onset of action. This research evaluates real-world safety data after mirtazapine has already been approved and widely used, which makes it directly relevant to clinical medicine. This data helps clinicians to understand which adverse effects occur most frequently, as well as underrepresented risks and at-risk populations. This data can help physicians create individualized treatment plans and improve risk monitoring. Additionally, the study provides valuable recommendations for adjustments in clinical practice, such as early and long-term monitoring of adverse effects, as well as specific consideration of ECG and suicide risk. There is high clinical relevance because mirtazapine is widely prescribed and may be specifically chosen for “reduced adverse effects”, but the information gathered in this research is important for informing patients and clinicians about the risks and benefits. In the future, additional studies are needed to confirm the enhanced signals and to update treatment guidelines. The research reinforces the need for early and ongoing monitoring, especially for suicide risk and cardiac effects.